Inhibikase Therapeutics Inc (IKT) Price Prediction & ForecastIKTInhibikase Therapeutics Inc

Alphio's IKT stock price prediction model matches the current Inhibikase Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.56 (-0.63%). The 1-week path is $1.58 (+1.05%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Inhibikase Therapeutics Inc is currently not a strong buy. The stock is trading at $1.54, which is close to its 52-week low of $1.39 and significantly below its 52-week high of $2.61. The RSI is at 34.034, indicating that the stock is in oversold territory, which could suggest a potential rebound. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term. Additionally, the company has reported consistent net losses, with a net income of -$19,591,231 in Q2 2026, raising concerns about its profitability. The main risk is the ongoing negative earnings trend, as evidenced by the EPS of -0.11 for the last quarter, which was worse than the market's expectations. Overall, while there may be a potential for recovery, the current financial instability suggests a cautious approach.

Inhibikase Therapeutics Inc (IKT) last closed at $1.5650001, gaining +5.74%. These facts feed the 1-day and 1-week IKT price prediction above.